28,257 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Acquired by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd acquired 28,257 shares of Arcturus Therapeutics, valued at approximately $299,000, representing about 0.10% ownership of the company.
• Invesco Ltd. significantly increased its stake in Arcturus by 83.1% during the first quarter, now holding 34,896 shares valued at $370,000.
• Arcturus Therapeutics reported earnings of ($0.34) per share, exceeding analysts' expectations, and generated revenue of $28.30 million, notably above the $17.64 million estimate.

Dynamic Technology Lab Private Ltd bought a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 28,257 shares of the biotechnology company's stock, valued at approximately $299,000. Dynamic Technology Lab Private Ltd owned about 0.10% of Arcturus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in Arcturus Therapeutics during the 1st quarter valued at $4,892,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Arcturus Therapeutics by 20.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company's stock worth $1,526,000 after purchasing an additional 24,583 shares during the period. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics in the first quarter worth about $128,000. Vestal Point Capital LP bought a new stake in shares of Arcturus Therapeutics in the first quarter worth about $2,243,000. Finally, AlphaQuest LLC increased its holdings in Arcturus Therapeutics by 394.0% during the 1st quarter. AlphaQuest LLC now owns 35,282 shares of the biotechnology company's stock valued at $374,000 after purchasing an additional 28,140 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ARCT shares. HC Wainwright began coverage on Arcturus Therapeutics in a report on Thursday, September 4th. They issued a "buy" rating and a $60.00 price objective for the company. Citigroup restated a "buy" rating and set a $49.00 target price (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a report on Tuesday, August 12th. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Finally, Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $50.57.

Arcturus Therapeutics Trading Up 8.7%

ARCT traded up $1.57 during trading on Thursday, reaching $19.62. The stock had a trading volume of 1,110,126 shares, compared to its average volume of 473,100. The company has a market capitalization of $532.88 million, a price-to-earnings ratio of -8.80 and a beta of 2.39. The stock's 50 day moving average is $15.73 and its two-hundred day moving average is $13.48. Arcturus Therapeutics Holdings Inc. has a one year low of $8.04 and a one year high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. The firm had revenue of $28.30 million for the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.